Related Experiment Video
Updated: Nov 30, 2025

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
Published on: August 2, 2018
N6-methyladenosine methyltransferase plays a role in hypoxic preconditioning partially through the interaction with
Yamin Su1, Rongfeng Xu1, Rui Zhang1
1Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Abstract:
N6-methyladenosine (m6A), a methylation in the N6 position of adenosine especially in the mRNA, exerts diverse physiological and pathological functions. However, the precise role of m6A methylation in hypoxic preconditioning (HPC) is still unknown. Here, we observed that HPC treatment protected H9c2 cells against H2O2-induced injury, upregulated the m6A level in the total RNA and the expression of methyltransferase like 3 (METTL3), methyltransferase like 14 (METTL14), and long noncoding RNA (lncRNA) H19. Either knockdown of METTL3 or METTL14 notably reversed the HPC-induced enhancement of cell viability, anti-apoptosis ability, and H19 expression. Methylated RNA immunoprecipitation (IP) indicated that knockdown of METTL3 or METTL14 decreased m6A level in the lncRNA H19. Gain-of-function assay demonstrated that H19 overexpression could partially rescue the decreased protection mediated by METTL3 or METTL14 knockdown in HPC-treated H9c2 cells. RNA binding protein immunoprecipitation (RIP) assay showed that METTL3 and METTL14 could directly bind with H19. Our study identified a novel pattern of posttranscriptional regulation in HPC treatment. Since METTL3, METTL14, and lncRNA H19 were involved in HPC protection, they could be considered as potential biomarkers and therapeutic targets in HPC-derived cardiac rehabilitation and therapeutic approaches.
Insights
Hypoxic preconditioning (HPC) protects cells from injury by increasing N6-methyladenosine (m6A) levels. This involves methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), and H19 long noncoding RNA (lncRNA), offering potential therapeutic targets.
Area of Science:
- Molecular Biology
- Cell Biology
- Epigenetics
Background:
- N6-methyladenosine (m6A) is a crucial RNA modification with diverse biological roles.
- The function of m6A in hypoxic preconditioning (HPC) remains largely unexplored.
- HPC confers cellular protection against various stresses.
Purpose of the Study:
- To investigate the role of m6A methylation in HPC-induced protection of H9c2 cells.
- To identify key molecular players involved in m6A regulation during HPC.
- To explore the potential of m6A-related factors as therapeutic targets in cardiac rehabilitation.
Main Methods:
- H9c2 cells were subjected to hypoxic preconditioning (HPC) and H2O2-induced injury.
- Expression levels of m6A, METTL3, METTL14, and H19 were quantified.
- Knockdown and overexpression strategies were employed for METTL3, METTL14, and H19.
- Methylated RNA immunoprecipitation (mRIP) and RNA binding protein immunoprecipitation (RIP) assays were performed.
Main Results:
- HPC treatment enhanced H9c2 cell viability and reduced apoptosis.
- HPC upregulated total RNA m6A levels, METTL3, METTL14, and H19 expression.
- Knockdown of METTL3 or METTL14 diminished HPC-induced protection and H19 upregulation.
- METTL3 and METTL14 directly bind to H19, regulating its m6A modification.
Conclusions:
- A novel posttranscriptional regulatory mechanism involving m6A, METTL3, METTL14, and H19 is identified in HPC.
- METTL3, METTL14, and H19 are critical mediators of HPC-induced cellular protection.
- These factors represent potential biomarkers and therapeutic targets for HPC-related cardiac rehabilitation.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
MicroRNAs
MicroRNAs
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
RNA Editing
